Allergan Has Plans to Raise $350 Million

Allergan Inc., maker of the Botox anti-wrinkle treatment, plans to raise as much as $350 million through the sale of debt securities, according to a document it filed Friday with the Securities and Exchange Commission.

The Irvine company registered an offering to sell the securities when financing needs arise or market conditions become favorable.

Allergan will use the proceeds for general corporate purposes, including debt repayment or refinancing, working capital, capital expenditures and acquisitions.

Allergan stock rose $1 to close at $57.09 on the New York Stock Exchange.